AER 01
Alternative Names: AER-01Latest Information Update: 01 Aug 2023
At a glance
- Originator Aer Therapeutics
- Class Carbohydrates; Small molecules
- Mechanism of Action Mucin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 26 May 2023 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in Australia (Inhalation) (NCT05862623)
- 22 May 2023 Aer Therapeutics plans a phase I trial for Chronic obstructive pulmonary disease (In Volunteers) (Inhalation) in May 2023(NCT05862623)
- 14 May 2023 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) before May 2023